Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors

Journal of Clinical Investigation

Volumn 101, Issue 6, 1998, Pages 1233-1242

  Censier, Kathrin ^a   Urwyler, Albert ^a   Zorzato, Francesco ^b   Treves, Susan ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Ca2+ channel; Halothane; Hypermetabolism; Neuromuscular disorder; Skeletal muscle

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION; HALOTHANE; RYANODINE RECEPTOR;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALIGNANT HYPERTHERMIA; POINT MUTATION; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 0032521180     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI993     Document Type: Article

References (49)

1. Denborough, M.A., and R.R.H. Lovell. 1960. Anaesthetic deaths in a family. Lancet. 2:45.
2. MacLennan, D.H., and M.S. Phillips. 1992. Malignant hyperthermia. Science. 256:789-794.
3. Mickelson, J.R., E.M. Gallant, L.A. Litterer, K.M. Johnson, W.E. Rempel, and C.F. Louis. 1988. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J. Biol. Chem. 263:9310-9315.
4. MacLennan, D.H., C. Duff, F. Zorzato, J. Fujii, M. Phillips, R.G. Korneluk, W. Frodis, B.A. Britt, and R.G. Worton. 1990. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 343:559-561.
5. McCarthy, T.V., J.M.S. Healy, J.J.A. Heffron, M. Lehane, T. Deufel, F. Lehmann-Horn, M. Farrall, and K. Johnson. 1990. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 343:562-564.
6. Fujii, J., K. Otsu, F. Zorzato, S. de Leon, V.K. Khanna, J.E. Weiler, P.J. O'Brien, and D.H. MacLennan. 1991. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science. 253:448-451.
7. Gillard, E.F., K. Otsu, J. Fujii, V.K. Khanna, S. de Leon, J. Derdemezi, B.A. Britt, C.L. Duff, R.G. Worton, and D.H. MacLennan. 1991. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 11:751-755.
8. 2+. J. Gen. Physiol. 88:573-588.
9. 2+ regulation defects. Physiol. Rev. 76:537-591.
10. Keating, K.E., L. Giblin, P.J. Lynch, K.A. Quane, M. Lehane, J.J.A. Heffron, and T.V. McCarthy. 1997. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes. J. Med. Genet. 34:291-296.
11. Lynch, P.J., R. Krivosic-Horber, H. Reyford, N. Monnier, K. Quane, P. Adnet, G. Haudecoeur, I. Krivosic., T. McCarthy, and J. Lunardi. 1997. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred. Anesthesiology (Hagerst.). 86:620-626.
12. Levitt, R.C., N. Nouri, A.E. Jedlicka, V.A. McKusick, A.R. Marks, J.G. Shutack, J.E. Fletcher, H. Rosenberg, and D.A. Meyers. 1991. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics. 11: 543-547.
13. Levitt, R.C., A. Olckers, S. Meyers, J.E. Fletcher, H. Rosenberg, H. Isaacs, and D.A. Meyers. 1992. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics. 14:562-566.
14. Iles, D.E., F. Lehmann-Horn, S.W. Scherer, L.-C. Tsui, D.O. Weghuis, R.F. Suijkerbuijk, L. Heytens, G. Mikala, A. Schwartz, F.R. Ellis, et al. 1994. Localization of the gene encoding the a2/d-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum. Mol. Genet. 3:969-975.
15. Sudbrak, R., V. Procacco, M. Klausnitzer, J.L. Curran, K. Monsieurs, C. van Broeckhoven, R. Ellis, L. Heytens, E.J. Hartung, G. Kozak-Ribbens, et al. 1995. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am. J. Hum. Genet. 56:684-691.
16. Deufel, T., A. Golla, D. Iles, A. Meindl, T. Meitinger, D. Schindelhauer, A. DeVries, D. Pongratz, D.H. MacLennan, K.J. Johnson, and F. Lehmann-Horn. 1992. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am. J. Hum. Genet. 50:1151-1161.
17. 1984. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br. J. Anaesth. 56:1267-1269.
18. 2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. Biochem. J. 301:661-665.
19. 2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J. Biol. Chem. 269:9413-9415.
20. Richter, M., L. Schleithoff, T. Deufel, F. Lehmann-Horn, and A. Herrmann-Frank. 1997. Functional characterization of a distinct ryanodine receptor mutation in malgnant hyperthermia-susceptible muscle. J. Biol. Chem. 272: 5256-5260.
21. Urwyler, A., K. Censier, M.A. Kaufmann, and J. Drewe. 1994. Genetic effects on the variability of the halothane and caffeine muscle contracture tests. Anesthesiology (Hagerst.). 80:1287-1295.
22. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
23. Quane, K.A., J.M.S. Healy, K.E. Keating, B.M. Manning, F.J. Couch, L.M. Palmucci, C. Doriguzzi, T.H. Fagerlund, K. Berg, H. Ording, et al. 1993. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat. Genet. 5:51-55.
24. Keating, K.E., K.A. Quane, B.M. Manning, M. Lehane, E. Hartung, K. Censier, A. Urwyler, M. Klausnitzer, C.R. Muller, J.J.A. Heffron, and T.V. McCarthy. 1994. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum. Mol. Genet. 3:1855-1858.
25. Quane, K.A., K.E. Keating, B.M. Manning, J.M.S. Healy, K. Monsieurs, J.J.A. Heffron, M. Lehane, L. Heytens, R. Krivosic-Horber, P. Adnet, et al. 1994. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum. Mol. Genet. 3:471-476.
26. Otsu, K., M.S. Phillips, V.J. Khanna, S. de Leon, and D.H. MacLennan. 1992. Refinement of diagnostic assays for a probable causal mutation for porcine and human malignant hyperthermia. Genomics. 13:835-837.
27. Kunkel, T.A., J.D. Roberts, and R.A. Zakour. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154: 367-390.
28. Sanger, F., S. Nicklen, and A.R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74:5463-5467.
29. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
30. Saito, A., S. Seiler, A. Chu, and S. Fleischer. 1984. Preparation and morphology of sarcoplasmic reticulum terminal cisternae from rabbit skeletal muscle. J. Cell Biol. 99:875-885.
31. Thomas, A.P., and F. Delaville. 1991. The use of fluorescent indicators for measurements of cytosolic-free calcium concentration in cell populations and single cells. In Cellular Calcium. J.G. McCormack and P.H. Cobbold, editors. Oxford University Press, New York. 1-54.
32. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440-3450.
33. Westerblad, H., and D.G. Allen. 1996. Intracellular calibration of the calcium indicator indo-1 in isolated fibers of Xenopus muscle. Biophys. J. 71: 908-917.
34. Yasin, R., G. Van Beers, K.C.E. Nurse, S. Al-Ani, D.N. Landon, and E.J. Thompson. 1977. A quantitative technique for growing human adult skeletal muscle in culture starting from mononucleated cells. J. Neural. Sci. 32:347-359.
35. Zuurveld, J.G.E.M., A. Oosterhof, J.H. Veerkamp, and H.T.B. van Moerkerk. 1985. Oxidative metabolism of cultured human skeletal muscle cells in comparison with biopsy material. Biochim. Biophys. Acta. 844:1-8.
36. Allen, R.E., L.L. Rankin, E.A. Greene, L.K. Boxhorn, S.E. Johnson, R.G. Taylor, and P.R. Pierce. 1991. Desmin is present in proliferating rat muscle satellite cells but not in bovine muscle satellite cells. J. Cell. Physiol. 149: 525-535.
37. Blau, H.M., and C. Webster. 1981. Isolation and characterization of human muscle cells. Proc. Natl. Acad. Sci. USA. 78:5623-5627.
38. Censier, K., M.D. Sigg, and A. Urwyler. 1997. Altered calcium control mechanism in myotubes from subjects with malignant hyperthermia. Anesthesiology (Hagerst.). 87:A966. (Abstr.)
39. 2+ dependence of normal and malignant hyperthermic human muscle. Anesth. Analg. 160:492-498.
40. Fleischer, S., and M. Inui. 1989. Biochemistry and biophysics of excitation contraction coupling. Annu. Rev. Biophys. Biophys. Chem. 18:333-364.
41. 2+ release channels: does diversity in form equal diversity in function? Physiol. Rev. 76: 1027-1071.
42. 2+ release channel. Am. J. Physiol. 267:C1253-C1261.
43. 2+ in the ryanodine receptor of human malignant hyperthermia. Am. J. Physiol. 261:C237-C245.
44. Lopez, J.R., L. Alamo, C. Caputo, J. Wikinski, and D. Ledezma. 1985. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve. 8:355-358.
45. 2+] measured in vivo in patients susceptible to malignant hyperthermia. Anesthesiology (Hagerst.). 76:711-719.
46. Iaizzo, P.A., W. Klein, and F. Lehmann-Horn. 1988. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflügers Arch. 411:648-653.
47. 2+ and excitability. Cell Calcium. 21: 81-91.
48. Allen, D.G., and H. Westerbland. 1995. The effects of caffeine on intracellular calcium, force and the rate of relaxation of mouse skeletal muscle. J. Physiol. 487:331-342.
49. 2+ in intact rabbit cardiac myocytes. Biophys. J. 68:1453-1460.